已收盘 08-14 16:00:00 美东时间
+0.230
+5.64%
Ironwood Pharmaceuticals (NASDAQ:IRWD) raises FY2026 sales outlook from $450.000 million-$475.000 million to $460.000 million-$485.000 million vs $460.118 million estimate.
08-06 19:09
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.36 by 13.89 percent. This is a 121.43 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $113...
08-06 19:09
As the market moves through second-quarter earnings season, investors are paying close attention to small-cap stocks that combine solid profitability with attractive valuations. Price-to-earnings rat...
07-27 21:09
– Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and Patient Care – – Dr. Silber, a Drug Development Veteran, Will Lead Ironwood’s Next Phase of R&D Strategy and Execution – Ironwood Pharmaceuticals, ...
07-14 19:32
Ironwood Pharma ( ($IRWD) ) just unveiled an announcement. On June 15, 2026, Ir...
06-16 05:07
Ironwood Pharmaceuticals (($IRWD)) has held its Q1 earnings call. Read on for t...
06-02 08:30
Ironwood Pharmaceuticals (IRWD) announced on Wednesday that the Food and Drug Administration approved a label expansion for its AbbVie (ABBV)-partnered bowel disorder therapy Linzess to treat children...
05-27 23:00
As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factor...
05-26 22:20